Literature DB >> 16906107

The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty.

Vincent D Pellegrini1, Christopher T Donaldson, Daniel C Farber, Erik B Lehman, C McCollister Evarts.   

Abstract

Venous thromboembolism is the most common reason for readmission after total knee arthroplasty. Prospective contrast venography was conducted from 1984 to 2003 in 1321 patients undergoing total knee arthroplasty. Patients with deep venous thrombosis or pulmonary embolism were treated with warfarin; those with negative venograms received no further anticoagulation. From 1984 to 1992, patients not completing venography were discharged without warfarin; since 1993 patients without venography received warfarin for 6 weeks. Readmission for deep venous thrombosis, pulmonary embolism, or bleeding was tracked for 6 months. Venography was completed in 810 patients; 343 (42.3%) had deep venous thrombosis. Readmission for venous thromboembolism occurred in 0.6% of patients after total knee compared with 1.62% after total hip arthroplasty. Following total knee arthroplasty, patients discharged on warfarin (target INR 2.0) had a 0.21% readmission rate compared with 1.05% for patients with negative venograms discharged without further anticoagulation. One patient suffered a fatal pulmonary embolism after negative venography and no outpatient prophylaxis. Secondary prophylaxis with extended warfarin therapy reduced venous thromboembolism-related readmission. Surveillance venograms were a poor predictor of ultimate thromboembolism risk and need for extended anticoagulation therapy. We therefore recommend extended warfarin prophylaxis for all patients after hospital discharge following total knee arthroplasty.

Entities:  

Mesh:

Year:  2006        PMID: 16906107     DOI: 10.1097/01.blo.0000229357.19867.84

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

1.  Preventing venous thromboembolic disease in patients undergoing elective total hip and knee arthroplasty.

Authors:  Michael Mont; Joshua Jacobs; Jay Lieberman; Jay Parvizi; Paul Lachiewicz; Norman Johanson; William Watters
Journal:  J Bone Joint Surg Am       Date:  2012-04-18       Impact factor: 5.284

2.  Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey.

Authors:  B A Rogers; S Phillips; J Foote; K J Drabu
Journal:  Ann R Coll Surg Engl       Date:  2010-07-02       Impact factor: 1.891

Review 3.  A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

Authors:  Sam Schulman; Ammar Majeed
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

Review 4.  Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review.

Authors:  Davide Imberti; Chiara Dall'Asta; Matteo Giorgi Pierfranceschi
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

5.  Discontinuation of warfarin is unnecessary in total knee arthroplasty.

Authors:  David A Rhodes; Erik P Severson; Jeffrey T Hodrick; Harold K Dunn; Aaron A Hofmann
Journal:  Clin Orthop Relat Res       Date:  2010-01       Impact factor: 4.176

6.  Interruption of long-term warfarin is not necessary in patients undergoing total hip arthroplasty.

Authors:  Mohamed Mussa; Pratheek Chikkalur; James Isbister; Shreeram Deshpande; Eric Isbister
Journal:  J Orthop       Date:  2019-07-01

Review 7.  New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

Authors:  Ola E Dahl
Journal:  Vasc Health Risk Manag       Date:  2012-01-25

8.  Oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate.

Authors:  D Kendoff; C Perka; H M Fritsche; T Gehrke; R Hube
Journal:  Open Orthop J       Date:  2011-12-30

9.  Evaluation of etoricoxib in patients undergoing total knee replacement surgery in a double-blind, randomized controlled trial.

Authors:  Narinder Rawal; Eugene Viscusi; Paul M Peloso; Harold S Minkowitz; Liang Chen; Sandhya Shah; Anish Mehta; Denesh K Chitkara; Sean P Curtis; Dimitris A Papanicolaou
Journal:  BMC Musculoskelet Disord       Date:  2013-10-24       Impact factor: 2.362

Review 10.  Total knee arthroplasty: improving outcomes with a multidisciplinary approach.

Authors:  James E Feng; David Novikov; Afshin A Anoushiravani; Ran Schwarzkopf
Journal:  J Multidiscip Healthc       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.